Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Couch

Showing results (561-570 of 697) with videos related to

Pageof 70
Sort By:
American Journal of Human Genetics|September 20, 2016
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 RegulationMaya Ghoussaini, Juliet D French, Kyriaki Michailidou, et al.
Plos Genetics|November 10, 2010
Common genetic variants and modification of penetrance of BRCA2-associated breast cancerMia M Gaudet, Tomas Kirchhoff, Todd Green, et al.
Research Square|February 24, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 9, 2009
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association ConsortiumMia M Gaudet, Roger L Milne, Angela Cox, et al.
Communications Biology|January 19, 2022
Rare germline copy number variants (CNVs) and breast cancer riskJoe Dennis, Jonathan P Tyrer, Logan C Walker, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Cancer Medicine|July 4, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 70

Showing results (561-570 of 697) with videos related to

Sort By:
Pageof 70
American Journal of Human Genetics|September 20, 2016
Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 RegulationMaya Ghoussaini, Juliet D French, Kyriaki Michailidou, et al.
Plos Genetics|November 10, 2010
Common genetic variants and modification of penetrance of BRCA2-associated breast cancerMia M Gaudet, Tomas Kirchhoff, Todd Green, et al.
Research Square|February 24, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
Human Mutation|February 21, 2018
The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicityMara Colombo, Irene Lòpez-Perolio, Huong D Meeks, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|June 11, 2021
The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variantInge M M Lakeman, Alexandra J van den Broek, Juliën A M Vos, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 9, 2009
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association ConsortiumMia M Gaudet, Roger L Milne, Angela Cox, et al.
Communications Biology|January 19, 2022
Rare germline copy number variants (CNVs) and breast cancer riskJoe Dennis, Jonathan P Tyrer, Logan C Walker, et al.
JAMA Oncology|July 3, 2020
Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Valentina Silvestri, Goska Leslie, Daniel R Barnes, et al.
Cancer Medicine|July 4, 2023
Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survivalAnna Morra, Maartje A C Schreurs, Irene L Andrulis, et al.
British Journal of Cancer|November 19, 2009
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)A Osorio, R L Milne, G Pita, et al.
Pageof 70